Table 1 Characteristics of the included studies
Study | Patients(male) |  | Year(mean ± sd) |  | Intervention |  | Disease course(mean ± sd) | HBOT Efficacy | The CEBM Levels of Evidence | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IG | CG | Â | IG | CG | Â | IG | CG | Â | IG | CG | |||
Chen 2012 | 16(13) | 30(15) |  | 68.375 ± NR | 68.867 ± NR |  | HBOT + RDT + RT | RDT + RT |  | 1.75 ± NR(day) | 1.7 ± NR(day) | No difference (after 10 days) Beneficial (after 1 month) | Ib |
Chen 2018 | 25(10) | 25(11) |  | 61.3 ± 8.7 | 62.7 ± 12.5 |  | HBOT + APT | APT |  | NR | NR | Beneficial | IIb |
Nighoghossian 1995 | 17(9) | 17(12) |  | 53 ± 3 | 54 ± 3 |  | HBOT + RDT + RT | SHBOT + RDT + RT |  | 19 ± 2.7(hour) | 18 ± 3.2(hour) | Possibly beneficial | Ib |
Rusyniak 2003 | 17(12) | 16(10) |  | 75 ± NR | 68 ± NR |  | HBOT | SHBOT |  | NR | NR | No difference and Possibly harmful | Ib |
Zhu 2022 | 55(40) | 45(30) |  | 63.12 ± 9.74 | 61.18 ± 8.31 |  | HBOT + NWM | NWM |  | NR | NR | Beneficial | IIb |
-Imai 2006 | 19(10) | 19(12) |  | 74.9 ± 12.1 | 73.7 ± 10.6 |  | HBOT + IE + RDT | IE + RDT |  | 546 ± 856(min) | 668 ± 639(min) | Possibly beneficial | IIb |
Zhao 2008 | 50(28) | 62(36) |  | 65.7 ± 12.9 | 68.2 ± 13.7 |  | HBOT + RDT + RT | RDT + RT |  | NR | NR | Beneficial | IIb |
Dong 2023 | 40(27) | 40(25) |  | 67.25 ± 3.51 | 66.80 ± 3.65 |  | HBOT + NBP + OXR | NBP + OXR |  | 6.81 ± 2.43(day) | 7.10 ± 2.66(day) | Beneficial | IIb |